Skip to Content

Health

First Alzheimer’s drug to slow disease progression gets full FDA approval, likely triggering broader Medicare coverage

Originally Published: 06 JUL 23 06:47 ET Updated: 06 JUL 23 16:53 ET By Meg Tirrell, Nadia Kounang and Tami Luhby, CNN (CNN) — The US Food and Drug Administration on Thursday granted traditional full approval to the Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the memory-robbing disease. The decision is expected to

Continue Reading

First Alzheimer’s drug to slow disease progression gets full FDA approval, triggering broader Medicare coverage

CNN, WVIR By Meg Tirrell, Nadia Kounang and Tami Luhby, CNN (CNN) — The US Food and Drug Administration on Thursday granted traditional full approval to the Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the memory-robbing disease. The Centers for Medicare and Medicaid Services said Thursday that it will now expand

Continue Reading

First Alzheimer’s drug to slow disease progression gets full FDA approval, triggering broader Medicare coverage

By Meg Tirrell, Nadia Kounang and Tami Luhby, CNN (CNN) — The US Food and Drug Administration on Thursday granted traditional full approval to the Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the memory-robbing disease. The Centers for Medicare and Medicaid Services said Thursday that it will now expand coverage of

Continue Reading